Please Wait
Applying Filters...
menu
    • menu
    Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

    Data Compilation
    #PharmaFlow

    Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

    Stock Recap
    #PipelineProspector

    Menu

    DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 2,812Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Certificate Holder Certificate No. Substance Issue Date Status Type End Date Substance No.
    29/11/2025 PCAS
    France
    		 PCAS Ecully FR R1-CEP 2012-023 - Rev 01 Dorzolamide hydrochloride 2020-07-30 Withdrawn by Holder Chemical 2024-10-24 2359
    29/11/2025 TAPI Technology & API Services
    Israel
    		 TAPI NL B.V. Amsterdam NL CEP 2009-093 - Rev 04 Dorzolamide hydrochloride 2025-07-25 Valid Chemical 2359